Reuse Data From OEMs Could Jumpstart FDA Policy-making Effort
This article was originally published in The Gray Sheet
Executive Summary
Approximately 80% of commercially reprocessed biopsy forceps are not completely sterilized prior to reuse, according to data submitted to FDA by the Association of Disposable Device Manufacturers.
You may also be interested in...
FDA Reuse Policy Demands Data From Both OEMs And Reprocessors
FDA's revised policy on reprocessing of disposable medical devices would require manufacturers seeking to label a product as single-use only to submit data demonstrating that it cannot adequately be reprocessed, FDA staffers report.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.